Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00012467 · ClinicalTrials.gov registry record · Phase 2
Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis
A Phase 2 study, sponsored by InterMune.
- Completed
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
NCT00012467 is a Phase 2 study that has completed, run by InterMune. The registered enrollment target is 60 participants.
The verdict
NCT00012467, a Phase 2 study, has completed, sponsored by InterMune.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
Study Summary
The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.
Interventions
- DRUG Fluconazole
- DRUG Itraconazole
- DRUG Interferon gamma-1b
- DRUG Amphotericin B
- DRUG Flucytosine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2000-01 |
| Est. Completion | 2001-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00012467
The ClinicalTrials.gov registry entry for NCT00012467 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is InterMune, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fluconazole is the first listed.
NCT00012467 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00012467 about?
NCT00012467 is a clinical study titled "Safety and Antifungal Activity of Recombinant Interferon-Gamma 1b (rIFN-Gamma 1b) Given With Standard Therapy in Patients With Cryptococcal Meningitis". The purpose of this study is to examine the antifungal activity of recombinant interferon-gamma 1b (rIFN-gamma 1b) given with standard antifungal therapy.
What is the current status of trial NCT00012467?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2000-01. Estimated completion is 2001-07.
What interventions are being tested in trial NCT00012467?
The interventions under investigation include: Fluconazole (DRUG), Itraconazole (DRUG), Interferon gamma-1b (DRUG), Amphotericin B (DRUG), Flucytosine (DRUG).
Who is sponsoring clinical trial NCT00012467?
This trial is sponsored by InterMune, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.